1. Home
  2. Labeler Index
  3. Marlex Pharmaceuticals Inc
  4. 10135-680
  5. Product Images: Pilocarpine Hydrochloride

Product Images Pilocarpine Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Pilocarpine Hydrochloride NDC 10135-680 by Marlex Pharmaceuticals Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Pilocarpine hydrochloride tablets, USP contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in most non-polar solvents. Pilocarpine hydrochloride with a chemical name of (3S-cis)-2(3H)-Furanone, 3-ethyl-dihydro-4-[(1-methyl-1H- imidazol-5-yl) methyl] mono- hydrochloride, has a molecular weight of 244.72. - pilocarpine hydrochloride 01

Pilocarpine hydrochloride tablets, USP contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in most non-polar solvents. Pilocarpine hydrochloride with a chemical name of (3S-cis)-2(3H)-Furanone, 3-ethyl-dihydro-4-[(1-methyl-1H- imidazol-5-yl) methyl] mono- hydrochloride, has a molecular weight of 244.72. - pilocarpine hydrochloride 01

Clinical and Biochemical Measurments - pilocarpine hydrochloride 02

Clinical and Biochemical Measurments - pilocarpine hydrochloride 02

Head & Neck Cancer Patients: In controlled studies, 217 patients received pilocarpine, of whom 68% were men and 32% were women. Race distribution was 91% Caucasian, 8% Black, and 1% of other origin. Mean age was approximately 58 years. The majority of patients were between 50 and 64 years (51%), 33% were 65 years and older and 16% were younger than 50 years of age. The most frequent adverse experiences associated with pilocarpine hydrochloride tablets, USP were a consequence of the expected pharmacologic effects of pilocarpine. - pilocarpine hydrochloride 03

Head & Neck Cancer Patients: In controlled studies, 217 patients received pilocarpine, of whom 68% were men and 32% were women. Race distribution was 91% Caucasian, 8% Black, and 1% of other origin. Mean age was approximately 58 years. The majority of patients were between 50 and 64 years (51%), 33% were 65 years and older and 16% were younger than 50 years of age. The most frequent adverse experiences associated with pilocarpine hydrochloride tablets, USP were a consequence of the expected pharmacologic effects of pilocarpine. - pilocarpine hydrochloride 03

This appears to be a table that compares the incidence of adverse events (sweating, nausea, diarrhea, flushing, urinary frequency, dizziness, and vision changes) in a group of people who were given Pilocarpine HCI and a group of people who were given a placebo. The table provides counts or percentages of individuals who experienced each adverse event in each group.*

In addition, the following adverse events (3% incidence) were reported at dosages of 15-30 mg/day in the controlled clinical trials: - pilocarpine hydrochloride 04

In addition, the following adverse events (3% incidence) were reported at dosages of 15-30 mg/day in the controlled clinical trials: - pilocarpine hydrochloride 04

Sjogrens Syndrome Patients: In controlled studies, 376 patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was 84% Caucasian, 9% Oriental, 3% Black, and 4% of other origin. Mean age was 55 years. The majority of patients were between 40 and 69 years (70%), 16% were 70 years and older and 14% were younger than 40 years of age. Of these patients, 161/629 (89/376 receiving pilocarpine) were over the age of 65 years. The adverse events reported by those over 65 years and those 65 years and younger were comparable except for notable trends for urinary frequency, diarrhea, and dizziness. The incidences of urinary frequency and diarrhea in the elderly were about double those of the non-elderly. The incidence of dizziness was about three times as high in the elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebo-controlled studies, the most common adverse events related to drug use were sweating, urinary frequency, chills, and vasodilatation (flushing). The most commonly reported reason for patient discontinuation of treatment was sweating. Expected pharmacologic effects of pilocarpine include the following adverse experiences associated with pilocarpine hydrochloride tablets, USP: - pilocarpine hydrochloride 05

Sjogrens Syndrome Patients: In controlled studies, 376 patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was 84% Caucasian, 9% Oriental, 3% Black, and 4% of other origin. Mean age was 55 years. The majority of patients were between 40 and 69 years (70%), 16% were 70 years and older and 14% were younger than 40 years of age. Of these patients, 161/629 (89/376 receiving pilocarpine) were over the age of 65 years. The adverse events reported by those over 65 years and those 65 years and younger were comparable except for notable trends for urinary frequency, diarrhea, and dizziness. The incidences of urinary frequency and diarrhea in the elderly were about double those of the non-elderly. The incidence of dizziness was about three times as high in the elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebo-controlled studies, the most common adverse events related to drug use were sweating, urinary frequency, chills, and vasodilatation (flushing). The most commonly reported reason for patient discontinuation of treatment was sweating. Expected pharmacologic effects of pilocarpine include the following adverse experiences associated with pilocarpine hydrochloride tablets, USP: - pilocarpine hydrochloride 05

This appears to be a table regarding the comparison of adverse events in patients treated with Plocarpine HCI versus Placebo. The table lists the adverse events such as sweating, urinary frequency, nausea, flushing, rhinitis, diarrhea, and increased salivation. However, some parts of the text are not decipherable due to errors.*

In addition, the following adverse events (3% incidence) were reported at dosages of 20 mg/day in the controlled clinical trials: - pilocarpine hydrochloride 06

In addition, the following adverse events (3% incidence) were reported at dosages of 20 mg/day in the controlled clinical trials: - pilocarpine hydrochloride 06

PRINCIPAL DISPLAY PANELNDC 10135-0680-01PilocarpineHydrochlorideTablets, USP5 mgRx Only100 TABLETS - pilocarpine hydrochloride 07

PRINCIPAL DISPLAY PANELNDC 10135-0680-01PilocarpineHydrochlorideTablets, USP5 mgRx Only100 TABLETS - pilocarpine hydrochloride 07

This is a description of a medicine sold in the form of tablets. The medicine's name is Carpine and its active ingredient is listed as USP. The NDC code is 10135-0680-01 and the package contains 100 tablets. The rest of the text is not available as it contains unclear characters and nonsensical words.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.